이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ImmunoGen 과거 수익 실적

과거 기준 확인 0/6

ImmunoGen has been growing earnings at an average annual rate of 2.8%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 6.2% per year.

주요 정보

2.8%

수익 성장률

21.4%

EPS 성장률

Biotechs 산업 성장	-14.6%
매출 성장률	6.2%
자기자본 수익률	-113.0%
순이익	-210.3%
최근 수익 업데이트	30 Sep 2022

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

ImmunoGen 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

XTRA:IMU 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용
30 Sep 22	96	-201	88
30 Jun 22	89	-161	64
31 Mar 22	92	-129	50
31 Dec 21	70	-139	44
30 Sep 21	128	-71	40
30 Jun 21	137	-56	40
31 Mar 21	135	-49	40
31 Dec 20	132	-44	39
30 Sep 20	91	-71	39
30 Jun 20	86	-70	38
31 Mar 20	87	-89	37
31 Dec 19	82	-104	38
30 Sep 19	51	-151	38
30 Jun 19	48	-176	38
31 Mar 19	42	-174	38
31 Dec 18	53	-169	37
30 Sep 18	79	-140	36
30 Jun 18	77	-150	36
31 Mar 18	107	-117	36
31 Dec 17	115	-96	34
30 Sep 17	90	-117	33
30 Jun 17	89	-105	35
31 Mar 17	57	-142	35
31 Dec 16	49	-157	39
30 Sep 16	53	-156	38
30 Jun 16	60	-145	34
31 Mar 16	65	-129	35
31 Dec 15	57	-119	31

양질의 수익: IMU is currently unprofitable.

이익 마진 증가: IMU is currently unprofitable.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: IMU is unprofitable, but has reduced losses over the past 5 years at a rate of 2.8% per year.

성장 가속화: Unable to compare IMU's earnings growth over the past year to its 5-year average as it is currently unprofitable

수익 대 산업: IMU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).

자기자본 수익률

높은 ROE: IMU has a negative Return on Equity (-112.97%), as it is currently unprofitable.

ImmunoGen 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.15 loss in 2Q 2021)

First quarter 2022 earnings released: US$0.095 loss per share (vs US$0.17 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.14 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.17 loss in 1Q 2020)

Recent updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

ImmunoGen, Inc. Announces Executive Changes

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE

ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm)

ImmunoGen, Inc. Announces US Food and Drug Administration Grants Accelerated Approval of ELAHERE™ for the Treatment of Platinum-Resistant Ovarian Cancer

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen, Inc. Announces Departure of Kristen Harrington-Smith as Senior Vice President Chief Commercial Officer

ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

ImmunoGen, Inc. Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.15 loss in 2Q 2021)

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO

Immunogen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review

First quarter 2022 earnings released: US$0.095 loss per share (vs US$0.17 loss in 1Q 2021)

ImmunoGen, Inc. Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

ImmunoGen, Inc. Appoint Executives

Forecast to breakeven in 2024

ImmunoGen Appoints Mimi Huizinga as Senior Vice President and Head of Medical Affairs

Forecast to breakeven in 2024

ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.14 loss in 2Q 2020)

ImmunoGen, Inc. Announces Mature Data from Forward II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin in Recurrent Ovarian Cancer, Regardless of Platinum Status

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.17 loss in 1Q 2020)

ImmunoGen, Inc. Provides Revenue Guidance for the Year of 2021

Full year 2020 earnings released: US$0.25 loss per share (vs US$0.70 loss in FY 2019)

Revenue beats expectations

Executive Officer has left the company

Full year 2020 earnings released: US$0.25 loss per share (vs US$0.70 loss in FY 2019)

Revenue beats expectations

New 90-day high: €6.39

ImmunoGen, Inc. Enters into Collaboration and Option Agreement with Subsidiary of Jazz Pharmaceuticals plc

New 90-day high: €5.29

ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting

Third quarter 2020 earnings released: US$0.13 loss per share

Revenue beats expectations

New 90-day high: €4.98

ImmunoGen, Inc. Announces Executive Changes, Effective on January 1, 2021

ImmunoGen and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Announces Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China

New 90-day high: €4.63

ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMO

New 90-day low - €2.99

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기